{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:20:36Z","timestamp":1788304836396,"version":"build-2803163510"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jare.2026.06.030","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:12:53Z","timestamp":1783091573000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Involvement of cyclins in the pathogenesis of cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-0591","authenticated-orcid":false,"given":"Mohammad","family":"Taheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Shirvani-Farsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashdar Mahmud","family":"Hussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefe","family":"Abak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Liehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soudeh","family":"Ghafouri-Fard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1085-9161","authenticated-orcid":false,"given":"Aria","family":"Baniahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/gb4184","article-title":"Cyclin-dependent kinases","volume":"15","author":"Malumbres","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jare.2026.06.030_b0010","doi-asserted-by":"crossref","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy. 2025;10(1):11.","DOI":"10.1038\/s41392-024-02080-z"},{"issue":"Pt 3","key":"10.1016\/j.jare.2026.06.030_b0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1242\/jcs.99.3.669","article-title":"Conserved structural motifs in cyclins identified by sequence analysis","volume":"99","author":"Nugent","year":"1991","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jare.2026.06.030_b0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.apcsb.2023.02.001","article-title":"Cyclin-dependent kinases in cancer: role, regulation, and therapeutic targeting","volume":"135","author":"Gupta","year":"2023","journal-title":"Adv Protein Chem Struct Biol"},{"key":"10.1016\/j.jare.2026.06.030_b0030","doi-asserted-by":"crossref","unstructured":"Wang Q, Bode AM, Zhang T. Targeting CDK1 in cancer: mechanisms and implications. npj Precision Oncol. 2023;7(1):58.","DOI":"10.1038\/s41698-023-00407-7"},{"issue":"9","key":"10.1016\/j.jare.2026.06.030_b0035","article-title":"Mechanistic roles of transcriptional cyclin-dependent kinases in oncogenesis: implications for cancer therapy","volume":"17","author":"Alrouji","year":"2025","journal-title":"Cancers [Internet]"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12885-017-3941-x","article-title":"Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma","volume":"18","author":"Ren","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jare.2026.06.030_b0045","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6180425","article-title":"MiR-195 inhibits tumor growth and metastasis in papillary thyroid carcinoma cell lines by targeting CCND1 and FGF2","volume":"2017","author":"Yin","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"11","key":"10.1016\/j.jare.2026.06.030_b0050","doi-asserted-by":"crossref","first-page":"8697","DOI":"10.1007\/s13277-015-3623-8","article-title":"MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression","volume":"36","author":"Long","year":"2015","journal-title":"Tumour Biol"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095216","article-title":"A new lncRNA, APTR, associates with and represses the CDKN1A\/p21 promoter by recruiting polycomb proteins","volume":"9","author":"Negishi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13008-025-00144-2","article-title":"LncRNA-ANRIL regulates CDKN2A to promote malignant proliferation of Kasumi-1 cells","volume":"20","author":"Xu","year":"2025","journal-title":"Cell Div"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0065","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1038\/s41598-022-20769-5","article-title":"CDK4\/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1\/S transition","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.12.036","article-title":"Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication","volume":"186","author":"Zeng","year":"2023","journal-title":"Cell"},{"issue":"7553","key":"10.1016\/j.jare.2026.06.030_b0075","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jare.2026.06.030_b0080","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/cncr.21767","article-title":"Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma","volume":"106","author":"Rosen","year":"2006","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.jare.2026.06.030_b0085","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/onc.2012.387","article-title":"Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress","volume":"32","author":"Jones","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0090","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1038\/s41467-019-13105-5","article-title":"CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer","volume":"10","author":"Nie","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.06.030_b0095","article-title":"Cyclin E expression is associated with high levels of replication stress in triple-negative breast cancer","volume":"6(1):40","author":"Guerrero Llobet","year":"2020","journal-title":"npj Breast Cancer"},{"issue":"23","key":"10.1016\/j.jare.2026.06.030_b0105","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1158\/1078-0432.CCR-17-1544","article-title":"Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer","volume":"23","author":"Doostan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jare.2026.06.030_b0125","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1158\/0008-5472.CAN-15-1646","article-title":"Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells","volume":"76","author":"Lucenay","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-022-00311-6","article-title":"Co-targeting CDK2 and CDK4\/6 overcomes resistance to aromatase and CDK4\/6 inhibitors in ER+ breast cancer","volume":"6","author":"Al-Qasem","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"40","key":"10.1016\/j.jare.2026.06.030_b0140","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi3821","article-title":"LncRNA EILA promotes CDK4\/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein","volume":"9","author":"Cai","year":"2023","journal-title":"Sci Adv"},{"issue":"14","key":"10.1016\/j.jare.2026.06.030_b0145","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jare.2026.06.030_b0150","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor\u2013positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1158\/1078-0432.CCR-22-1281","article-title":"Palbociclib rechallenge for hormone receptor-positive\/HER-negative advanced breast cancer: findings from the phase II BioPER trial","volume":"29","author":"Albanell","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.jare.2026.06.030_b0160","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1080\/15384101.2020.1804720","article-title":"The requirement for cyclin E in c-Myc overexpressing breast cancers","volume":"19","author":"Zhou","year":"2020","journal-title":"Cell Cycle (Georgetown, Tex)"},{"issue":"11","key":"10.1016\/j.jare.2026.06.030_b0165","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/15384047.2020.1818518","article-title":"Cyclin E overexpression confers resistance to trastuzumab through noncanonical phosphorylation of SMAD3 in HER2+ breast cancer","volume":"21","author":"Decker","year":"2020","journal-title":"Cancer Biol Ther"},{"issue":"24","key":"10.1016\/j.jare.2026.06.030_b0170","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","article-title":"Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0175","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201378","article-title":"Quantitative profiling of adaptation to cyclin E overproduction","volume":"5","author":"Limas","year":"2022","journal-title":"Life Sci Alliance"},{"issue":"22","key":"10.1016\/j.jare.2026.06.030_b0180","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/0008-5472.CAN-23-4130","article-title":"Low\u2013molecular weight cyclin E confers a vulnerability to PKMYT1 inhibition in triple-negative breast cancer","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.jare.2026.06.030_b0185","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400938R","article-title":"UA influences the progression of breast cancer via the AhR\/p27\/cyclin E pathway","volume":"38","author":"Wang","year":"2024","journal-title":"FASEB J"},{"issue":"10","key":"10.1016\/j.jare.2026.06.030_b0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41389-020-00270-2","article-title":"Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors","volume":"9","author":"Kok","year":"2020","journal-title":"Oncogenesis"},{"issue":"50","key":"10.1016\/j.jare.2026.06.030_b0195","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1038\/s41388-022-02527-z","article-title":"Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0200","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190381","article-title":"Down-regulation of CCNE1 expression suppresses cell proliferation and sensitizes gastric carcinoma cells to Cisplatin","volume":"39","author":"Zhang","year":"2019","journal-title":"Biosci Rep"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1533034614568098","article-title":"Prognostic value of expression of cyclin E in gastrointestinal cancer: a systematic review and meta-analysis","volume":"15","author":"Huang","year":"2015","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jare.2026.06.030_b0115","doi-asserted-by":"crossref","unstructured":"Kumari S, Puneet, Prasad SB, Yadav SS, Kumar M, Khanna A, et al. Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer. Medical oncology (Northwood, London, England). 2016;33(5):40.","DOI":"10.1007\/s12032-016-0754-8"},{"issue":"8","key":"10.1016\/j.jare.2026.06.030_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152434","article-title":"CCNE1 amplification is associated with liver metastasis in gastric carcinoma","volume":"215","author":"Kim","year":"2019","journal-title":"Pathol- Res Pract"},{"key":"10.1016\/j.jare.2026.06.030_b0210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2018.04.037","article-title":"Cyclin E overexpression confers resistance to the CDK4\/6 specific inhibitor palbociclib in gastric cancer cells","volume":"430","author":"Min","year":"2018","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0215","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbrc.2018.01.046","article-title":"Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1","volume":"496","author":"Zhang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.15430\/JCP.2019.24.3.192","article-title":"\u03b2-carotene inhibits expression of c-Myc and cyclin E in Helicobacter pylori-infected gastric epithelial cells","volume":"24","author":"Kim","year":"2019","journal-title":"J. Cancer Prevent"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0225","first-page":"3375","article-title":"Knockdown of long noncoding RNA GHET1 inhibits cell\u2011cycle progression and invasion of gastric cancer cells","volume":"18","author":"Xia","year":"2018","journal-title":"Mol Med Rep"},{"issue":"01","key":"10.1016\/j.jare.2026.06.030_b0230","first-page":"44","article-title":"Analysis of cyclin E co-expression genes reveals nuclear transcription factor Y subunit alpha is an oncogene in gastric cancer","volume":"5","author":"Bie","year":"2019","journal-title":"Chron Dis Transl Med"},{"key":"10.1016\/j.jare.2026.06.030_b0235","article-title":"Bruceine D inhibits cell proliferation through downregulating LINC01667\/MicroRNA-138-5p\/Cyclin E1 axis in gastric cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"issue":"18","key":"10.1016\/j.jare.2026.06.030_b0240","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1158\/0008-5472.CAN-17-1240","article-title":"FBW7 loss promotes chromosomal instability and tumorigenesis via cyclin E1\/CDK2-mediated phosphorylation of CENP-A","volume":"77","author":"Takada","year":"2017","journal-title":"Cancer Res"},{"issue":"37","key":"10.1016\/j.jare.2026.06.030_b0245","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1073\/pnas.1807155115","article-title":"Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma","volume":"115","author":"Sonntag","year":"2018","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0250","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1038\/s41467-018-07552-9","article-title":"Cyclin A2\/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress","volume":"9","author":"Bayard","year":"2018","journal-title":"Nat Commun"},{"issue":"34","key":"10.1016\/j.jare.2026.06.030_b0255","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1038\/onc.2014.373","article-title":"Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability","volume":"34","author":"Jiang","year":"2015","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0260","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202256052","article-title":"SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth","volume":"24","author":"Jin","year":"2023","journal-title":"EMBO Rep"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0265","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1073\/pnas.1711477115","article-title":"Kinase-independent function of E-type cyclins in liver cancer","volume":"115","author":"Geng","year":"2018","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12964-019-0398-3","article-title":"Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression","volume":"17","author":"Xu","year":"2019","journal-title":"Cell Commun Signaling"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0275","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3892\/ol.2015.3436","article-title":"Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique","volume":"10","author":"Shan","year":"2015","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.jare.2026.06.030_b0280","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.3390\/ijms25074060","article-title":"The clinicopathological significance of the cyclin D1\/E1\u2013cyclin-dependent kinase (CDK2\/4\/6)\u2013retinoblastoma (RB1\/pRB1) pathway in epithelial ovarian cancers","volume":"25","author":"Lashen","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.jare.2026.06.030_b0285","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/onc.2015.301","article-title":"PKCiota promotes ovarian tumor progression through deregulation of cyclin E","volume":"35","author":"Nanos-Webb","year":"2016","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0100","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-011-1638-4","article-title":"Targeting low molecular weight cyclin E (LMW-E) in breast cancer","volume":"132","author":"Nanos-Webb","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41065-023-00273-0","article-title":"CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis","volume":"160","author":"Zheng","year":"2023","journal-title":"Hereditas"},{"key":"10.1016\/j.jare.2026.06.030_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.148957","article-title":"The dual role of cyclin D1: Unraveling its tumor-promoting mechanisms and opportunities for therapeutics","volume":"333","author":"Taheri","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0295","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-017-4294-5","article-title":"High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers","volume":"164","author":"Ahlin","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jare.2026.06.030_b0300","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2147\/OTT.S309091","article-title":"High expression of cyclin D1 is an independent marker for favorable prognosis in middle eastern breast cancer","volume":"14","author":"Siraj","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jare.2026.06.030_b0320","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.895729","article-title":"Prognostic and predictive value of CCND1\/Cyclin D1 amplification in breast cancer with a focus on postmenopausal patients: a systematic review and meta-analysis","volume":"13","author":"Jeffreys","year":"2022","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0345","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1158\/1535-7163.MCT-17-0537","article-title":"Combined inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer","volume":"17","author":"Michaloglou","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.jare.2026.06.030_b0305","first-page":"18656","article-title":"Positive expression of cyclin D1 is an indicator for the evaluation of the prognosis of breast cancer","volume":"8","author":"Guo","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0350","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12885-015-1266-1","article-title":"Altered PPP2R2A and cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer","volume":"15","author":"Beca","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0355","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1186\/s12885-019-6262-4","article-title":"AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells","volume":"19","author":"De Amicis","year":"2019","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.jare.2026.06.030_b0360","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.7150\/thno.23877","article-title":"Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome","volume":"8","author":"Wang","year":"2018","journal-title":"Theranostics"},{"issue":"47","key":"10.1016\/j.jare.2026.06.030_b0340","doi-asserted-by":"crossref","first-page":"81754","DOI":"10.18632\/oncotarget.19953","article-title":"Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth","volume":"8","author":"Pestell","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0365","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12029-018-0079-2","article-title":"Prognostic value of cyclin D1 and CD44 expression in gastric adenocarcinoma","volume":"50","author":"Ibrahim","year":"2019","journal-title":"J Gastrointest Cancer"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0370","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/path.5246","article-title":"RN181 is a tumour suppressor in gastric cancer by regulation of the ERK\/MAPK\u2013cyclin D1\/CDK4 pathway","volume":"248","author":"Wang","year":"2019","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0375","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41420-022-01079-1","article-title":"CHREBP suppresses gastric cancer progression via the cyclin D1-Rb-E2F1 pathway","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Discovery"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0325","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1096\/fj.201903217R","article-title":"MiR-129-5p induces cell cycle arrest through modulating HOXC10\/Cyclin D1 to inhibit gastric cancer progression","volume":"34","author":"He","year":"2020","journal-title":"FASEB J"},{"issue":"10","key":"10.1016\/j.jare.2026.06.030_b0380","first-page":"634","article-title":"Curcumin promoted miR-34a expression and suppressed proliferation of gastric cancer cells","volume":"34","author":"Sun","year":"2019","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3727\/096504018X15193469240508","article-title":"MicroRNA-623 targets cyclin D1 to inhibit cell proliferation and enhance the chemosensitivity of cells to 5-fluorouracil in gastric cancer","volume":"27","author":"Jiang","year":"2018","journal-title":"Oncol Res"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0390","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/cimb44030093","article-title":"Cyclin D1 serves as a poor prognostic biomarker in stage I gastric cancer","volume":"44","author":"Go","year":"2022","journal-title":"Curr Issues Mol Biol"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0395","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1002\/jcp.27083","article-title":"Leukemia inhibitory factor inhibits the proliferation of gastric cancer by inducing G1-phase arrest","volume":"234","author":"Xu","year":"2019","journal-title":"J Cell Physiol"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0400","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/15384047.2019.1679554","article-title":"TRIM58 suppresses the tumor growth in gastric cancer by inactivation of \u03b2-catenin signaling via ubiquitination","volume":"21","author":"Liu","year":"2020","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jare.2026.06.030_b0405","doi-asserted-by":"crossref","unstructured":"Wang H, Ge X, Qu H, Wang N, Zhou J, Xu W, et al. Glycyrrhizic acid inhibits proliferation of gastric cancer cells by inducing cell cycle arrest and apoptosis. Cancer Management and Research. 2020;12(null):2853-61.","DOI":"10.2147\/CMAR.S244481"},{"issue":"14","key":"10.1016\/j.jare.2026.06.030_b0410","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1111\/jcmm.16664","article-title":"METTL16 promotes cell proliferation by up\u2010regulating cyclin D1 expression in gastric cancer","volume":"25","author":"Wang","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0415","first-page":"2739","article-title":"Overexpression of IC53d promotes the proliferation of gastric cancer cells by activating the AKT\/GSK3\u03b2\/cyclinD1 signaling pathway","volume":"41","author":"Lin","year":"2019","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0420","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1002\/jcb.26491","article-title":"Up-regulated WDR5 promotes gastric cancer formation by induced cyclin D1 expression","volume":"119","author":"Sun","year":"2018","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0425","first-page":"1831","article-title":"Transcription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancer","volume":"15","author":"Ji","year":"2018","journal-title":"Exp Ther Med"},{"issue":"8","key":"10.1016\/j.jare.2026.06.030_b0430","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/cbf.3361","article-title":"SIX1 is upregulated in gastric cancer and regulates proliferation and invasion by targeting the ERK pathway and promoting epithelial-mesenchymal transition","volume":"36","author":"Xie","year":"2018","journal-title":"Cell Biochem Funct"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0435","first-page":"1579","article-title":"Resveratrol inhibits the growth of gastric cancer via the Wnt\/\u03b2-catenin pathway","volume":"16","author":"Dai","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jare.2026.06.030_b0440","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/med-2019-0005","article-title":"METTL3 promotes the proliferation and mobility of gastric cancer cells","volume":"14","author":"Lin","year":"2019","journal-title":"Open Med (Warsaw, Poland)"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0445","first-page":"2119","article-title":"Long non\u2011coding RNA LINC00857 promotes gastric cancer cell proliferation and predicts poor patient survival","volume":"16","author":"Pang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jare.2026.06.030_b0450","doi-asserted-by":"crossref","unstructured":"Mo W.L, Jiang T.J., Zhang L., Lu Q.C., Li J., Gu W.D., Cheng Y., Wang H.T. Circular RNA hsa_circ_0000467 Promotes the Development of Gastric Cancer by Competitively Binding to MicroRNA miR-326-3p.Biomed Res Int 2020; 6 (4030826). eCollection 2020.","DOI":"10.1155\/2020\/4030826"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0455","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/2211-5463.12639","article-title":"CORO1C expression is associated with poor survival rates in gastric cancer and promotes metastasis invitro","volume":"9","author":"Cheng","year":"2019","journal-title":"FEBS Open Bio"},{"issue":"24","key":"10.1016\/j.jare.2026.06.030_b0460","doi-asserted-by":"crossref","first-page":"38811","DOI":"10.18632\/oncotarget.16402","article-title":"Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-\u03b2\/Smad-regulated liver cancer stem cell-like cells","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0465","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hep.29781","article-title":"Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system","volume":"68","author":"Wu","year":"2018","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.jare.2026.06.030_b0470","unstructured":"Won C, Lee CS, Lee J-K, Kim T-J, Lee K-H, Yang YM, et al. CADPE suppresses cyclin D1 expression in hepatocellular carcinoma by blocking IL-6-induced STAT3 activation. Anticancer Res. 2010;30(2):481-8."},{"issue":"20","key":"10.1016\/j.jare.2026.06.030_b0475","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020326","article-title":"Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0480","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020572","article-title":"Prognostic potential of cyclin D1 expression in colorectal cancer","volume":"12","author":"Jun","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0485","first-page":"57","article-title":"Prognostic value of IMP3 and cyclin D1 expression in patients with colorectal cancer","volume":"13","author":"Mohamed","year":"2022","journal-title":"Middle East Journal of Cancer"},{"issue":"21","key":"10.1016\/j.jare.2026.06.030_b0330","article-title":"A necessary role for cyclin D2 induction during colon cancer progression mediated by L1","volume":"13","author":"Saha","year":"2024","journal-title":"Cells [Internet]"},{"issue":"11","key":"10.1016\/j.jare.2026.06.030_b0490","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.21873\/anticanres.13839","article-title":"The prognostic value of G1 cyclins, p21 and Rb protein in patients with colon cancer","volume":"39","author":"Palaiologos","year":"2019","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0495","article-title":"Prognostic value of combined; Cox-2, cyclin D1 and P21 expression in colorectal cancer (CRC) patients: an immunohistochemical study","volume":"8","author":"Amir","year":"2018","journal-title":"Open J Pathol"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0500","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/sj.bjc.6602709","article-title":"Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas","volume":"93","author":"Mermelshtein","year":"2005","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0505","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41419-018-1263-9","article-title":"CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt\/\u03b2-catenin signaling via transactivation of GSK-3\u03b2 and Axin2 expression","volume":"10","author":"Yu","year":"2019","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0510","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13000-023-01410-z","article-title":"Clinical value of Cyclin D1 and P21 in the differential diagnosis of papillary thyroid carcinoma","volume":"18","author":"Wang","year":"2023","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0515","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1038\/s41598-020-61985-1","article-title":"Enhanced expression of Cyclin D1 and C-myc, a prognostic factor and possible mechanism for recurrence of papillary thyroid carcinoma","volume":"10","author":"Sanjari","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0520","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13000-015-0262-8","article-title":"Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential","volume":"10","author":"Lamba Saini","year":"2015","journal-title":"Diagn Pathol"},{"issue":"11","key":"10.1016\/j.jare.2026.06.030_b0525","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/cancers10110437","article-title":"CCND1 splice variant as a novel diagnostic and predictive biomarker for thyroid cancer","volume":"10","author":"Jeon","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0530","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/ERC-15-0162","article-title":"MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma","volume":"23","author":"Romitti","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jare.2026.06.030_b0535","article-title":"Mitochondrial respiration inhibition suppresses papillary thyroid carcinoma via PI3K\/Akt\/FoxO1\/cyclin D1 pathway","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0540","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ymthe.2018.12.015","article-title":"DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 expression","volume":"27","author":"Chen","year":"2019","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0545","first-page":"513","article-title":"Impact of cyclin D1 and heterogeneous nuclear ribonucleoprotein-K (HnRNP-K) on urinary bladder carcinogenesis","volume":"19","author":"Aboushousha","year":"2018","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0550","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41467-019-09179-w","article-title":"Targeting glutamine-addiction and overcoming CDK4\/6 inhibitor resistance in human esophageal squamous cell carcinoma","volume":"10","author":"Qie","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0555","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/cancers11060760","article-title":"Amplification of the EGFR and CCND1 are coordinated and play important roles in the progression of oral squamous cell carcinomas","volume":"11","author":"Chien","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0560","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174309","article-title":"Knocking-down of CREPT prohibits the progression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc expression","volume":"12","author":"Ma","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0565","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-015-0322-4","article-title":"miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6","volume":"14","author":"Xia","year":"2015","journal-title":"Mol Cancer"},{"issue":"19","key":"10.1016\/j.jare.2026.06.030_b0570","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/onc.2015.316","article-title":"Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K\/AKT\/HIF-1\u03b1\/cyclin D1 pathway","volume":"35","author":"Chen","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.jare.2026.06.030_b0575","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cca.2019.08.023","article-title":"Genistein upregulates cyclin D1 and CDK4 expression and promotes the proliferation of ovarian cancer OVCAR-5 cells","volume":"512","author":"Wang","year":"2021","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0580","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1208\/s12248-023-00874-7","article-title":"Pharmacodynamics of cyclin D1 degradation in ovarian cancer xenografts with repeated oral SHetA2 dosing","volume":"26","author":"Sharma","year":"2023","journal-title":"AAPS J"},{"issue":"11","key":"10.1016\/j.jare.2026.06.030_b0585","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.1007\/s13277-015-3620-y","article-title":"Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients\u2019 outcome","volume":"36","author":"Dragoj","year":"2015","journal-title":"Tumor Biol"},{"issue":"10","key":"10.1016\/j.jare.2026.06.030_b0310","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1074\/jbc.M110.170720","article-title":"Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function","volume":"286","author":"Comstock","year":"2011","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0315","doi-asserted-by":"crossref","first-page":"G884","DOI":"10.1152\/ajpgi.00471.2009","article-title":"Cyclin D1 regulates hepatic estrogen and androgen metabolism","volume":"298","author":"Mullany","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0335","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cam4.2152","article-title":"Prognostic role of cyclin D2\/D3 in multiple human malignant neoplasms: a systematic review and meta-analysis","volume":"8","author":"Ding","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0590","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/geno.1996.0112","article-title":"Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors","volume":"32","author":"Li","year":"1996","journal-title":"Genomics"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0595","first-page":"1153","article-title":"Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma: involvement of cyclin C in osteosarcoma","volume":"18","author":"Ohata","year":"2006","journal-title":"Int J Mol Med"},{"issue":"10","key":"10.1016\/j.jare.2026.06.030_b0600","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jgg.2011.09.002","article-title":"Dysregulation of CDK8 and Cyclin C in tumorigenesis","volume":"38","author":"Xu","year":"2011","journal-title":"J Genetics Genomics = Yi Chuan Xue Bao"},{"issue":"16","key":"10.1016\/j.jare.2026.06.030_b0605","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.230029","article-title":"Synergistic repression of thyroid hyperplasia by cyclin C and Pten","volume":"132","author":"Jezek","year":"2019","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jare.2026.06.030_b0625","doi-asserted-by":"crossref","unstructured":"Jiang H-Y, Chen Y-I, Xu X-X, Li C-Y, Chen Y, Li D-P, et al. Ubiquitylation of cyclin C by HACE1 regulates cisplatin-associated sensitivity in gastric cancer. Clin Transl Med. 2022;12(3):e770.","DOI":"10.1002\/ctm2.770"},{"key":"10.1016\/j.jare.2026.06.030_b0610","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.L7983","article-title":"Dissecting the dual role of cyclin C in tumor suppression","volume":"36","author":"Willis","year":"2022","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0615","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0002-9440(10)64433-1","article-title":"Genome-wide appraisal of thyroid cancer progression","volume":"161","author":"Wreesmann","year":"2002","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0620","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3324\/haematol.2024.285701","article-title":"Cyclin C promotes development and progression of B-cell acute lymphoblastic leukemia by counteracting p53-mediated stress responses","volume":"110","author":"Trifinopoulos","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0630","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/j.1460-2075.1992.tb05135.x","article-title":"Cyclin a is required at two points in the human cell cycle","volume":"11","author":"Pagano","year":"1992","journal-title":"EMBO J"},{"issue":"20","key":"10.1016\/j.jare.2026.06.030_b0635","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.cub.2003.09.024","article-title":"Cdk2 knockout mice are viable","volume":"13","author":"Berthet","year":"2003","journal-title":"Curr Biol"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0640","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bbrc.2008.11.077","article-title":"Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2","volume":"378","author":"Joshi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0645","doi-asserted-by":"crossref","DOI":"10.1172\/JCI131517","article-title":"Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer","volume":"131","author":"Guo","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jare.2026.06.030_b0650","article-title":"Comprehensive analysis of cyclin family gene expression in colon cancer","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0655","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/PAI.0000000000000839","article-title":"PTEN loss and cyclin A2 upregulation define a PI3K\/AKT pathway activation in Helicobacter pylori-induced MALT and DLBCL gastric lymphoma with features of MALT","volume":"29","author":"Ben Younes","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol: AIMM"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0665","article-title":"Prognostic significance of cyclins A2, B1, D1, and E1 and CCND1 numerical aberrations in oral squamous cell carcinomas","volume":"2018","author":"Monteiro","year":"2018","journal-title":"Anal Cell Pathol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0670","first-page":"46","article-title":"CSN1 facilitates proliferation and migration of hepatocellular carcinoma cells by upregulating cyclin A2 expression","volume":"23","author":"Fu","year":"2021","journal-title":"Mol Med Rep"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0660","first-page":"1715","article-title":"Cyclin a correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer","volume":"35","author":"Cybulski","year":"2015","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0675","doi-asserted-by":"crossref","first-page":"21701","DOI":"10.1038\/s41598-024-72174-9","article-title":"Y-box binding protein 1\/cyclin A1 axis specifically promotes cell cycle progression at G2\/M phase in ovarian cancer","volume":"14","author":"Murakami","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2026.06.030_b0680","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2016.08.007","article-title":"Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells","volume":"67","author":"Huang","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0685","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1371\/journal.pbio.0050123","article-title":"Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression","volume":"5","author":"Lindqvist","year":"2007","journal-title":"PLoS Biol"},{"issue":"12","key":"10.1016\/j.jare.2026.06.030_b0690","first-page":"5246","article-title":"Menadione induces G2\/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1","volume":"8","author":"Lee","year":"2016","journal-title":"Am J Transl Res"},{"issue":"12","key":"10.1016\/j.jare.2026.06.030_b0695","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41419-018-1211-8","article-title":"CREPT\/RPRD1B associates with Aurora B to regulate Cyclin B1 expression for accelerating the G2\/M transition in gastric cancer","volume":"9","author":"Ding","year":"2018","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0700","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.18632\/oncotarget.13653","article-title":"Prognostic role of cyclin B1 in solid tumors: a meta-analysis","volume":"8","author":"Ye","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0705","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/carcin\/bgm269","article-title":"Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis","volume":"29","author":"Song","year":"2008","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0720","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s10020-021-00302-6","article-title":"Phosphorylation of islet-1 serine 269 by CDK1 increases its transcriptional activity and promotes cell proliferation in gastric cancer","volume":"27","author":"Shi","year":"2021","journal-title":"Mol Med"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0725","first-page":"1605","article-title":"Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress\u2011mediated apoptosis and G2\/M phase arrest","volume":"44","author":"Ren","year":"2020","journal-title":"Oncol Rep"},{"issue":"18","key":"10.1016\/j.jare.2026.06.030_b0730","doi-asserted-by":"crossref","first-page":"16366","DOI":"10.18632\/oncotarget.3879","article-title":"PBRM1 suppresses bladder cancer by cyclin B1 induced cell cycle arrest","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0735","doi-asserted-by":"crossref","first-page":"16226","DOI":"10.1038\/s41598-023-42801-y","article-title":"A pancancer analysis of the oncogenic role of cyclin B1 (CCNB1) in human tumors","volume":"13","author":"Dai","year":"2023","journal-title":"Sci Rep"},{"issue":"34","key":"10.1016\/j.jare.2026.06.030_b0710","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1038\/sj.onc.1207757","article-title":"Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells","volume":"23","author":"Yuan","year":"2004","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.jare.2026.06.030_b0715","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/sj.onc.1209202","article-title":"Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo","volume":"25","author":"Yuan","year":"2006","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0740","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41467-018-04258-w","article-title":"Cyclin K regulates prereplicative complex assembly to promote mammalian cell proliferation","volume":"9","author":"Lei","year":"2018","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.jare.2026.06.030_b0745","doi-asserted-by":"crossref","first-page":"11144","DOI":"10.7150\/thno.42578","article-title":"Cyclin K interacts with \u03b2-catenin to induce Cyclin D1 expression and facilitates tumorigenesis and radioresistance in lung cancer","volume":"10","author":"Yao","year":"2020","journal-title":"Theranostics"},{"issue":"39","key":"10.1016\/j.jare.2026.06.030_b0750","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205509119","article-title":"CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer","volume":"119","author":"Sun","year":"2022","journal-title":"PNAS"},{"issue":"8","key":"10.1016\/j.jare.2026.06.030_b0755","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/ijc.30864","article-title":"Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer","volume":"141","author":"Schecher","year":"2017","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109394","article-title":"Degradation of CCNK\/CDK12 is a druggable vulnerability of colorectal cancer","volume":"36","author":"Dieter","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.jare.2026.06.030_b0765","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59994","article-title":"Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation","volume":"9","author":"Lv","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.jare.2026.06.030_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114012","article-title":"Noncovalent CDK12\/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor","volume":"228","author":"Niu","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0775","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3892\/ol.2011.444","article-title":"Protein expression pattern in response to ionizing radiation in MCF-7 human breast cancer cells","volume":"3","author":"Jung","year":"2012","journal-title":"Oncol Lett"},{"issue":"13","key":"10.1016\/j.jare.2026.06.030_b0780","doi-asserted-by":"crossref","first-page":"9028","DOI":"10.1074\/jbc.M112.432005","article-title":"Interaction with cyclin H\/cyclin-dependent kinase 7 (CCNH\/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration","volume":"288","author":"Wang","year":"2013","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.jare.2026.06.030_b0785","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1007\/s10620-013-2597-x","article-title":"Low expression of cyclinH and cyclin-dependent kinase 7 can decrease the proliferation of human esophageal squamous cell carcinoma","volume":"58","author":"Zhang","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0790","first-page":"483","article-title":"Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle","volume":"37","author":"Yu","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jare.2026.06.030_b0800","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6646077","article-title":"Cyclin H regulates lung cancer progression as a carcinoma inducer","volume":"2021","author":"Mao","year":"2021","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0805","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12935-020-01406-5","article-title":"Cyclin H predicts the poor prognosis and promotes the proliferation of ovarian cancer","volume":"20","author":"Peng","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"23","key":"10.1016\/j.jare.2026.06.030_b0890","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1158\/1078-0432.CCR-15-1104","article-title":"Expression of CDK7, cyclin H, and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor-positive breast cancer","volume":"22","author":"Patel","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0815","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s13402-021-00636-7","article-title":"Atypical cyclin P regulates cancer cell stemness through activation of the WNT pathway","volume":"44","author":"S\u00e1nchez-Botet","year":"2021","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0825","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s13046-018-0973-2","article-title":"Cyclin G2 suppresses Wnt\/\u03b2-catenin signaling and inhibits gastric cancer cell growth and migration through Dapper1","volume":"37","author":"Gao","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0895","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3892\/or.2016.4876","article-title":"MicroRNA-340 promotes the tumor growth of human gastric cancer by inhibiting cyclin G2","volume":"36","author":"Yin","year":"2016","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0795","doi-asserted-by":"crossref","first-page":"16995","DOI":"10.1038\/s41598-021-96528-9","article-title":"Detection of fusion gene transcripts in the blood samples of prostate cancer patients","volume":"11","author":"Yu","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0810","doi-asserted-by":"crossref","first-page":"11797","DOI":"10.1038\/s41598-018-30307-x","article-title":"The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration","volume":"8","author":"S\u00e1nchez-Botet","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0820","doi-asserted-by":"crossref","first-page":"10228","DOI":"10.1038\/s41598-017-10770-8","article-title":"A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer","volume":"7","author":"Gasa","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0830","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s13277-013-1389-4","article-title":"Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell","volume":"35","author":"Cui","year":"2014","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0835","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-024-03097-6","article-title":"The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer","volume":"43","author":"Heidari Horestani","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jare.2026.06.030_b0840","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70691","article-title":"Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130\/RBL2","volume":"10","author":"Enrico","year":"2021","journal-title":"Elife"},{"issue":"20","key":"10.1016\/j.jare.2026.06.030_b0845","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101443","article-title":"E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition","volume":"38","author":"Burdova","year":"2019","journal-title":"EMBO J"},{"issue":"21","key":"10.1016\/j.jare.2026.06.030_b0850","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.18632\/aging.204372","article-title":"The deubiquitylase USP7 is a novel cyclin F-interacting protein and regulates cyclin F protein stability","volume":"14","author":"Sharma","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0855","first-page":"123","article-title":"Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: comprehensive analysis of the pathways altered due to cyclin F upregulation","volume":"40","author":"Gagat","year":"2018","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0860","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040859","article-title":"Expression of genomic instability-related molecules: cyclin F, RRM2 and SPDL1 and their prognostic significance in pancreatic adenocarcinoma","volume":"13","author":"Klimaszewska-Wi\u015bniewska","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0865","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cas.12100","article-title":"Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis","volume":"104","author":"Fu","year":"2013","journal-title":"Cancer Sci"},{"issue":"31","key":"10.1016\/j.jare.2026.06.030_b0870","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026623","article-title":"Increased expression of cyclin F in liver cancer predicts poor prognosis: a study based on TCGA database","volume":"100","author":"Zelong","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.jare.2026.06.030_b0875","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1109378","article-title":"CCNF is a potential pancancer biomarker and immunotherapy target","volume":"13","author":"Wei","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0880","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12935-021-01833-y","article-title":"Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"7","key":"10.1016\/j.jare.2026.06.030_b0900","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1128\/MCB.15.7.3463","article-title":"Different roles for cyclins D1 and E in regulation of the G1-to-S transition","volume":"15","author":"Resnitzky","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.jare.2026.06.030_b0905","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41389-020-00270-2","article-title":"Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors","volume":"9","author":"Kok","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jare.2026.06.030_b0910","series-title":"Therapeutic potential of Cell Cycle Kinases in Breast Cancer","first-page":"253","article-title":"Novel CDK inhibitors in breast cancer","author":"Mir","year":"2023"},{"issue":"6","key":"10.1016\/j.jare.2026.06.030_b0915","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7668","key":"10.1016\/j.jare.2026.06.030_b0920","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0925","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41467-025-67865-4","article-title":"CDK2 inhibitor BLU-222 synergizes with CDK4\/6 inhibitors in drug resistant breast cancers through p21\/p27 induction","volume":"17","author":"Luo","year":"2026","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0930","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tcr-2025-2105","article-title":"Precision targeting of CCNE1-amplified tumors\u2014lessons from BLU-222 and beyond","volume":"15","author":"Rantanen","year":"2026","journal-title":"Transl Cancer Res"},{"issue":"9","key":"10.1016\/j.jare.2026.06.030_b0935","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.21037\/tcr-2025-81","article-title":"Recent advances in development of CDK7 inhibitors and their clinical trials: a narrative review","volume":"14","author":"Zhang","year":"2025","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jare.2026.06.030_b0940","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1182\/blood-2025-6542","article-title":"Trilaciclib for the prevention of chemotherapy-induced myelosuppression: a systematic review and meta-analysis","volume":"146","author":"Ahmed","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jare.2026.06.030_b0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101103","article-title":"Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment","volume":"76","author":"Glaviano","year":"2024","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.jare.2026.06.030_b0950","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41392-025-02475-6","article-title":"Novel CDK2\/4\/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial","volume":"10","author":"Yin","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.jare.2026.06.030_b0955","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10495-026-02340-z","article-title":"Celecoxib potentiates ribociclib-induced apoptosis and anti-tumor activity by co-targeting COX-2\/NF-\u03baB and PI3K\/AKT\/mTOR pathways in hormone receptor-positive\/HER2-negative breast cancer","volume":"31","author":"Han","year":"2026","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.jare.2026.06.030_b0965","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000847","article-title":"CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy","volume":"8","author":"Lai","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jare.2026.06.030_b0970","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"Proteolysis targeting chimeras (PROTACs) \u2014 past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today Technol"},{"issue":"8042","key":"10.1016\/j.jare.2026.06.030_b0975","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jare.2026.06.030_b0980","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2025.6585","article-title":"Overall survival with first-line vs second-line CDK4\/6 inhibitor use in advanced breast cancer: a randomized clinical trial","volume":"12","author":"Wortelboer","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jare.2026.06.030_b0995","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-025-01310-w","article-title":"NF-\u03baB in inflammation and cancer","author":"Mao","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b1000","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2174\/1871520621666210908101751","article-title":"Naturally sourced CDK inhibitors and current trends in structure-based synthetic anticancer drug design by crystallography","volume":"22","author":"Nandi","year":"2022","journal-title":"Anti-Cancer Agents Med Chem-Anti-Cancer Agents)"},{"issue":"14","key":"10.1016\/j.jare.2026.06.030_b1005","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.2174\/1386207325666210917111847","article-title":"Natural inhibitors against potential targets of cyclooxygenase, lipoxygenase and leukotrienes","volume":"25","author":"Dey","year":"2022","journal-title":"Comb Chem High Throughput Screen"},{"issue":"3","key":"10.1016\/j.jare.2026.06.030_b1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e14569","article-title":"Natural product-driven dual COX-LOX inhibitors: overview of recent studies on the development of novel anti-inflammatory agents","volume":"9","author":"Mukhopadhyay","year":"2023","journal-title":"Heliyon"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600514X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600514X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:36:27Z","timestamp":1783456587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209012322600514X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":197,"alternative-id":["S209012322600514X"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.06.030","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involvement of cyclins in the pathogenesis of cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}